CF Services Helps Lower Co-Pay for Cayston for Participants in Federal Employee Health Benefit Program

November 2, 2012

Beginning Jan. 1, 2013, federal employees who participate in the Blue Cross and Blue Shield Federal Employee Plan (BCBS FEP) will have lower out-of-pocket costs for the inhaled antibiotic Cayston® when purchased through the CF Services pharmacy or any of the three other pharmacies that distribute Cayston.

To help reduce out-of-pocket costs for people with cystic fibrosis who take Cayston, the CF Services’ case management team worked over the past year to urge the Office of Personnel Management, which oversees BCBS FEP, to change its benefits for specialty drugs to treat rare diseases, such as Cayston, that are distributed by a limited number of pharmacies. 

Currently, Cayston is considered a non-preferred brand drug by BCBS FEP and is subject to a high co-pay of 45 percent when purchased at out-of-network pharmacies. 

Through the successful efforts of CF Services, in 2013 BCBS FEP enrollees will be able to receive in-network benefits when purchasing Cayston from CF Services or any of the three other pharmacies that distribute this life-saving drug.

“Federal employees with cystic fibrosis or who have dependents with CF will now be able to save thousands of dollars in out-of-pocket costs annually,” said Robert J. Beall, Ph.D., president and CEO of the Cystic Fibrosis Foundation. “We are proud of the hard work of the CF Services team that contributed to this much-needed change, and for their commitment to making vital therapies more accessible and affordable for people with CF.”   

The CF Services pharmacy is a subsidiary of the CF Foundation. In October 2012, the CF Foundation entered into an alliance with Walgreens, giving the national drug store chain a significant ownership stake in CF Services.

For more information: